Cure My Disease

Don't miss your cure!

 Log in / Sign up

New bronchitis drug shows promise in large trial

NCT ID NCT07111468

Symptom relief Sponsor: Yuhan Corporation Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 3 trial tested a new drug called YHP2401 against two other drugs for acute bronchitis. 286 adults with cough and phlegm took one of the treatments for 7 days. The goal was to see if YHP2401 works better at reducing symptoms.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
YHP2401 (an experimental drug for acute bronchitis)
What this could lead to
If it works, this could offer a more effective treatment for acute bronchitis symptoms like cough and phlegm.
What could go wrong
This is a completed Phase 3 trial, but results are not yet public. The drug may not prove superior to existing treatments, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

286 people

The number who actually took part.

Started

Aug 2025

Finished

Jan 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

19 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male and female participants 19 years ≤ age ≤ 80 years * Patients with acute bronchitis presenting with productive cough symptoms within 48 hours prior to Visit 2 (Baseline) * BSS total score ≥ 5 at Visit 2, including Cough score ≥ 2, Sputum score ≥ 1 * Patients who voluntarily signed the consent form Exclusion Criteria: * Severe lung disease as determined by the investigator * Clinically significant abnormal findings or signs on chest X-ray suggesting diagnoses other than acute bronchitis * Active infection requiring systemic antibiotic treatment * Patients who need to take contraindicated concomitant medications

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute bronchitis are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

bronchitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute bronchitis

Contacts and locations

Locations

  • Hallym University Chuncheon Sacred Heart Hospital

    Chuncheon, 24253, South Korea

  • Kangbuk Samsung Hospital

    Seoul, 03181, South Korea

  • Kangdong Sacred Heart Hospital

    Seoul, 05355, South Korea

  • Konkuk University Medical Center

    Seoul, 05030, South Korea

  • Korea University Guro Hospital

    Seoul, 08308, South Korea

  • SMG-SNU Boramae Medical Center

    Seoul, 07061, South Korea

  • Soonchunhyang University Hospital Bucheon

    Bucheon-si, 14584, South Korea

  • The Catholic University of Korea, Eunpyeong St.Mary's Hospital

    Seoul, 03312, South Korea

  • The Catholic University of Korea, Uijeongbu St. Mary's Hospital

    Uijeongbu-si, 11765, South Korea

  • Ulsan University Hospital

    Ulsan, 44033, South Korea

  • Wonkwang University Hospital

    Iksan, 54538, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.